Fairvalue-Calculator Fairvalue-Calculator

Olympus Corporation (OLYMY) Fair Value & Analysis

Healthcare · US · Market cap $11.0B

Price$10.01
Fair Value$6.19
Upside-38.2%
Quality97/100
Evidence: High Range $4.63 – $9.55

Analysis

Olympus Corporation (OLYMY) currently trades at $10.01, while our model-based Fair Value estimate is $6.19 — implying the stock looks roughly 38.2% overvalued today. We read business quality at 97/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

About the company

Olympus Corporation, together with its subsidiaries, engages in the manufacture and sale of medical equipment in Japan, America, the Middle East, Asia, and Oceania. It operates through two segments, "Gastrointestinal Solutions and Surgical & Interventional Solutions. The company offers gastrointestinal Solutions products offer gastrointestinal endoscopes, gastroenterology devices, and medical services. The Surgical & Interventional Solutions provides urology, respiratory, surgical endoscopes, energy devices, ENT products, and gynecology products. It also provides respiratory products comprising bronchoscopy systems and devices, lung cancer products, and chronic obstructive pulmonary disease products; urology products consisting of visualization, stone management, benign prostatic hyperplasia (BPH), and BPH + bladder cancer products; surgical products, such as surgical endoscopy systems, advanced energy devices, surgical microscope, integrated procedure room solutions, and rhino-lary…

Open the full interactive analysis →

Similar stocks

Abbott Laboratories, (ABTT34) -20% Stryker Corporation (S1YK34) -45% Medtronic plc (MDT) -27% Boston Scientific Corporation (B1SX34) -5% Edwards Lifesciences Corporation (EW) -52% Siemens Healthineers AG (SEMHF) +11%

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.